Comparative Pharmacology
Head-to-head clinical analysis: AGGRENOX versus EFFIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRENOX versus EFFIENT.
AGGRENOX vs EFFIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aggrenox is a combination of dipyridamole and aspirin. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased extracellular adenosine which stimulates platelet adenylate cyclase, increasing cAMP levels and inhibiting platelet aggregation. Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 synthesis, thereby reducing platelet aggregation.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation.
One capsule (dipyridamole 200 mg plus aspirin 25 mg) orally twice daily.
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. In patients weighing <60 kg, maintenance dose is 5 mg orally once daily.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate terminal half-life 3-6 hours (dose-dependent). Dipyridamole: terminal half-life approximately 10-12 hours. Clinical context: Typical twice-daily dosing maintains therapeutic antiplatelet effect.
The terminal elimination half-life of the active metabolite is about 7.6 hours (range 2-15 hours). Clinically, this supports once-daily dosing.
Aspirin: renal elimination of salicylate and metabolites (primarily salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, and gentisic acid) accounts for >90% of a dose. Dipyridamole: primarily biliary excretion as glucuronide conjugates (enteric recycling); renal excretion accounts for <5% of unchanged drug.
Approximately 68% of the dose is excreted in urine as inactive metabolites, and about 27% in feces.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent